Вернуться к статье
Monitoring of the Apixaban’s pharmacodynamics in patients with non-valvular atrial fibrillation
Figure 1 - Correlation between anti-Xa activity and plasma concentration of the direct factor Xa inhibitor, apixaban. The arrow indicates concentration levels corresponding to the geometric mean values of Cmax
modified according to R. Kreutz et al., 2017